Martin J H J, Symonds A
Division of Biomedical Sciences, School of Applied Sciences, University of Wolverhampton, Wolverhampton, WV1 1SB, UK.
Oncol Rep. 2002 Mar-Apr;9(2):379-82.
We investigated the effect of toremifene, interferon-alpha2a, interferon-alpha2b and interferon-alpha2c, singly and in combination for their effect on the growth of ZR-75-1 human breast cancer cells. Median effect analysis was used to determine synergistic or additive effects. Anti-proliferative studies showed that the growth of ZR-75-1 cells was inhibited to a greater extent by combination treatment with toremifene plus interferon-alpha2a, resulting in a synergistic interaction (CI <1) for all concentrations tested. A combination of toremifene plus interferon-alpha2b resulted in a synergistic interaction (CI <1) for the two highest concentrations of toremifene (10(-6) and 10(-7) M) and an additive effect (CI approximately equal to 1) for the lower concentrations (10(-8) to 10(-10) M). When toremifene was combined with interferon-alpha2c no additive or synergistic interaction was determined.
我们研究了托瑞米芬、干扰素α2a、干扰素α2b和干扰素α2c单独及联合使用对ZR-75-1人乳腺癌细胞生长的影响。采用中位效应分析来确定协同或相加作用。抗增殖研究表明，托瑞米芬与干扰素α2a联合治疗对ZR-75-1细胞生长的抑制作用更强，在所有测试浓度下均产生协同相互作用（CI<1）。托瑞米芬与干扰素α2b联合使用时，在托瑞米芬的两个最高浓度（10⁻⁶和10⁻⁷ M）下产生协同相互作用（CI<1），而在较低浓度（10⁻⁸至10⁻¹⁰ M）下产生相加作用（CI约等于1）。当托瑞米芬与干扰素α2c联合使用时，未确定有相加或协同相互作用。
